Balyasny Asset Management
IBIO icon

Balyasny Asset Management’s iBio IBIO Stock Holding History

Balyasny Asset Management’s Portfolio IBIO Stock Details IBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.92M Sell
1,010,955
-85,224
-8% -$198K ﹤0.01% 1798
2025
Q4 		$2.12M Buy
1,096,179
+1,085,779
+10,440% +$1.48M ﹤0.01% 1830
2025
Q3 		$8.61K Buy
+10,400
New +$7.99K ﹤0.01% 2839

Other funds holding IBIO

AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Balyasny Asset Management's IBIO Position: Q1 2026 in Review

Balyasny Asset Management reduced its iBio (IBIO) stake by 7.8% in Q1 2026, selling an estimated $198K and leaving 1,010,955 shares worth $1.92M. The position accounts for ﹤0.01% of the portfolio, ranked #1798.

Balyasny Asset Management first reported a position in IBIO in Q3 2025 and has held it in 3 quarters since. The position peaked at $2.12M in Q4 2025. 52 funds tracked by Wall St. Rank hold IBIO as of Q1 2026.

  • Balyasny Asset Management held 1,010,955 shares of iBio worth $1.92M as of Q1 2026.
  • Balyasny Asset Management sold 85,224 iBio shares in Q1 2026, an estimated $198K.
  • iBio made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1798 holding.
  • Balyasny Asset Management first reported a position in iBio in Q3 2025 and has held it in 3 quarters since.
  • Balyasny Asset Management's iBio position peaked at $2.12M in Q4 2025.
  • 52 funds tracked by Wall St. Rank held iBio as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.